HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV

CompletedOBSERVATIONAL
Enrollment

3,127

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

December 12, 2024

Study Completion Date

December 12, 2024

Conditions
Cervical CancerHuman Papilloma VirusHuman Immunodeficiency VirusHPV-Related Carcinoma
Interventions
PROCEDURE

Blood collection

Blood collection at enrollment visit

PROCEDURE

Oral, cervicovaginal and anal specimen collection

Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits

PROCEDURE

Anoscopy & Biopsy of Acetowhite Lesions

Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH

PROCEDURE

Colposcopy & Biopsy of Acetowhite Lesions

Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV

PROCEDURE

Ablative Treatment

Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy

PROCEDURE

LEEP (Loop Electrosurgical Excision Procedure)

Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible

Trial Locations (1)

Unknown

Rwanda Military Hospital, Kigali

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rwanda Military Hospital

OTHER

collaborator

University of Rwanda

OTHER

lead

Montefiore Medical Center

OTHER

NCT05247853 - HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV | Biotech Hunter | Biotech Hunter